USA - engelsk - NLM (National Library of Medicine)

virtus pharmaceuticals - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 0.2 mg in 1 ml - contraindicated in people with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

neogen, n.v. - colecalciferol - cápsula mole - 1000 u.i. - colecalciferol 0.025 mg - colecalciferol - n/a - duração do tratamento: longa duração

USA - engelsk - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - doxercalciferol (unii: 3diz9lf5y9) (doxercalciferol - unii:3diz9lf5y9) - doxercalciferol 2 ug in 1 ml - doxercalciferol injection is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. doxercalciferol injection should not be given to patients with a tendency towards hypercalcemia or current evidence of vitamin d toxicity. doxercalciferol injection is contraindicated in patients with previous hypersensitivity to doxercalciferol or any of its ingredients (see warnings and adverse reactions ).

USA - engelsk - NLM (National Library of Medicine)

sandoz inc - doxercalciferol (unii: 3diz9lf5y9) (doxercalciferol - unii:3diz9lf5y9) - doxercalciferol 2 ug in 1 ml - doxercalciferol injection is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. doxercalciferol injection should not be given to patients with a tendency towards hypercalcemia or current evidence of vitamin d toxicity. doxercalciferol injection is contraindicated in patients with previous hypersensitivity to doxercalciferol or any of its ingredients (see warnings and adverse reactions ).

USA - engelsk - NLM (National Library of Medicine)

akorn - doxercalciferol (unii: 3diz9lf5y9) (doxercalciferol - unii:3diz9lf5y9) - doxercalciferol 4 ug in 2 ml - - doxercalciferol injection is indicated for the treatment of secondary hyperparathyroidism in adult patients with ckd on dialysis. doxercalciferol is contraindicated in patients with: - hypercalcemia [see warnings and precautions (5.1)] - vitamin d toxicity [see warnings and precautions (5.1)] - known hypersensitivity to doxercalciferol or any of the inactive ingredients of doxercalciferol injection; serious hypersensitivity reactions including anaphylaxis and angioedema have been reported [see warnings and precautions (5.3), adverse reactions (6.2)]. risk summary the limited available data with doxercalciferol in pregnant women are insufficient to identify a drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the mother and fetus associated with chronic kidney disease in pregnancy [see clinical considerations] . in reproduction studies in rats and rabbits administered doxercalciferol during organogenesis at up to 20 mcg/kg/day and 0.1 mcg/kg/da

USA - engelsk - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - doxercalciferol (unii: 3diz9lf5y9) (doxercalciferol - unii:3diz9lf5y9) - doxercalciferol 0.5 ug - doxercalciferol capsules is contraindicated in patients with: risk summary: the limited available data with doxercalciferol in pregnant women are insufficient to identify a drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the mother and fetus associated with chronic kidney disease in pregnancy [see clinical considerations ]. in reproduction studies in rats and rabbits administered doxercalciferol during organogenesis at up to 20 mcg/kg/day and 0.1 mcg/kg/day, respectively (approximately 25 times (rats) and less than (rabbits) the maximum recommended human oral dose of 60 mcg/week based on mcg/m2 body surface area), no adverse developmental effects were observed [see data ]. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20

USA - engelsk - NLM (National Library of Medicine)

kaiser foundation hospitals - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules, usp are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules, usp are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

USA - engelsk - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules, usp are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules, usp are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

USA - engelsk - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules, usp are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules, usp are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

USA - engelsk - NLM (National Library of Medicine)

blenheim pharmacal, inc. - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules, usp are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules, usp are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.